Abstract:Objective Hypoxic–ischemic encephalopathy (HIE) is a leading cause of morbidity and mortality in neonates. Therapeutic hypothermia (TH) has improved outcomes and mortality in infants with >36 weeks' gestational age (GA) with moderate-to-severe HIE. There are limited data on the safety and efficacy of TH in preterm infants with HIE. This study describes our experience and examines the safety of TH in neonates with <36 weeks' GA. Study Design A single-center, retrospective study of preterm neonates born at <36 weeks' GA with moderate-to-severe HIE and treated with TH, compared to a cohort of term neonates with HIE (≥37 weeks' GA), was conducted. The term cohort was matched for degree of background abnormality on electroencephalogram, sex, inborn versus outborn status, and birth year. Medical records were reviewed for pregnancy and delivery complications, need for transfusion, sedation and antiseizure medications, electroencephalography and imaging findings, and in-hospital mortality. Results Forty-two neonates born at <36 weeks' GA with HIE received TH between 2005 and 2022. Data from 42 term neonates were analyzed for comparison. The average GA of the preterm cohort was 34.6 weeks and 39.3 weeks for the term cohort. Apgar scores, degree of acidosis, and need for blood product transfusions were similar between groups. Preterm infants were more likely to require inotropic support (55 vs. 29%, p = 0.026) and hydrocortisone (36 vs. 12%, p = 0.019) for hypotension. The proportion of infants without evidence of injury on magnetic resonance imaging was similar in both groups: 43 versus 50% in preterm and term infants, respectively. No significant difference was found in mortality between groups. Conclusion In this single-center cohort, TH in preterm infants appears to be as safe as in term infants, with no significant increase in intracranial bleeds or mortality. Preterm infants more frequently required inotropes and steroids for hypotension. Further research is needed to determine efficacy of TH in preterm infants. Key Points TH is used off-protocol in preterm infants. Preterm and term infants have similar mortality. Preterm cohort required more inotropic support. * These authors contributed equally to the manuscript . Received: 08 August 2023 Accepted: 19 January 2024 Accepted Manuscript online: 23 January 2024 Article published online: 08 February 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

Experiences of Therapeutic Hypothermia Therapy on Six Cases with Persistent: Pulmonary Hypertension and Moderate to Severe Hypoxic Ischemic Encephalopathy using Inhaled Nitric Oxide Therapy

Inhaled Nitric Oxide in Preterm and Term Neonates with Hypoxemic Respiratory Failure and Persistent Pulmonary Hypertension

Prevalence of Pulmonary Hypertension During Therapeutic Hypothermia for Hypoxic Ischemic Encephalopathy and Evaluation of Short-Term Outcomes

Therapeutic hypothermia in infants with hypoxic-ischemic encephalopathy and reversible persistent pulmonary hypertension: short-term hospital outcomes

Developmental outcomes in persistent pulmonary hypertension treated with nitric oxide therapy

Inhaled Nitric Oxide Therapy Decreases the Risk of Cerebral Palsy in Preterm Infants With Persistent Pulmonary Hypertension of the Newborn

24 Persistent pulmonary hypertension and short-term neurological outcomes in infants with hypoxic ischemic encephalopathy undergoing therapeutic hypothermia

Clinical analysis on mechanical ventilation combined with inhaled nitric oxide in the treat-ment of persistent pulmonary hypertension of newborn

Noninvasive inhaled nitric oxide for persistent pulmonary hypertension of the newborn: A single center experience

Inhaled nitric oxide in newborns with severe hypoxic respiratory failure

[Inhaled nitric oxide: a physiologic treatment of persistent pulmonary arterial hypertension in the newborn]

Inhaled Nitric Oxide for the Early Treatment of Persistent Pulmonary Hypertension of the Term Newborn: A Randomized, Double-Masked, Placebo-Controlled, Dose-Response, Multicenter Study

Inhaled nitric oxide in the treatment of moderate persistent pulmonary hypertension of the newborn: a randomized controlled, multicenter trial

[Evidence of Inhaled Nitric Oxide Therapy for Hypoxic Respiratory Failure in Term and Near-Term Infants].

Inhaled nitric oxide as a rescue therapy in a preterm neonate with severe pulmonary hypertension: a case report

Inhaled nitric oxide combining high frequency oscillatory ventilation and oral sildenafil for refractory persistent pulmonary hypertension of newborn

Single-center Experience with Therapeutic Hypothermia for Hypoxic–Ischemic Encephalopathy in Infants with <36 Weeks' Gestation

Inhaled nitric oxide for preterm infants with persistent pulmonary hypertension

Inhaled Nitric Oxide and Gentle Ventilation in the Treatment of Pulmonary Hypertension of the Newborn — a Single-Center, 5-Year Experience

Comparison of Different Treatments of Persistent Pulmonary Hypertension of the Newborn: A Systematic Review and Network Meta-Analysis

Neurodevelopmental and medical outcomes of persistent pulmonary hypertension in term newborns treated with nitric oxide